AZD0865

TargetMol
Product Code: TAR-T30250
Supplier: TargetMol
CodeSizePrice
TAR-T30250-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30250-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30250-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AZD0865 is an effective drug that inhibits gastric H(+), K(+) -ATPase activity and acid formation in vitro, with rapid onset.
CAS:
847574-05-4
Formula:
C21H26N4O2
Molecular Weight:
366.46
Purity:
0.98
SMILES:
Cc1cccc(c1CNc2cc(cn3c2nc(c3C)C)C(=O)NCCO)C

References

1. Dent J, Kahrilas PJ, Hatlebakk J, Vakil N, Denison H, Franz?n S, Lundborg P. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008 Jan;103(1):20-6. doi: 10.1111/j.1572-0241.2007.01544.x. PubMed PMID: 18184117. 2. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franz?n S, Hasselgren G. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1385-91. Epub 2007 Oct 22. PubMed PMID: 17950677. 3. Gedda K, Briving C, Svensson K, Maxvall I, Andersson K. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205. Epub 2006 Sep 24. PubMed PMID: 17081503. 4. Kirchhoff P, Andersson K, Socrates T, Sidani S, Kosiek O, Geibel JP. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G838-43. Epub 2006 Jun 22. PubMed PMID: 16798725.